Cannabis Terpenes Relieve Pain Through Adenosine Receptors

For most of cannabis’s modern history, terpenes were treated as garnish. They gave the plant its smell, nudged the high in subjective directions, and — if you trusted the entourage-effect literature — helped THC do its job a little better. The receptors that mattered for pain were CB1 and CB2. The terpenes were flavoring on top.

That story is collapsing. Over the past three years, a research group at the University of Arizona has published a sequence of papers showing that several cannabis terpenes produce real analgesia — comparable to a clinical dose of morphine in mouse models — without touching the cannabinoid receptors at all. The pathway is the adenosine A2A receptor (A2AR), a target in an entirely different drug-discovery neighborhood from anything cannabis has historically been associated with.

This is a coordinated body of work spanning Scientific Reports, Pain, Pharmacology Reports, and Neuroscience Letters, with mechanism locked down by pharmacological antagonism, CRISPR knockdown, and molecular modeling. If you care what cannabis is actually doing inside a body in pain, it is the most important pharmacological reframing of the past decade.

What Adenosine Receptors Actually Are

Adenosine is a small signaling molecule your body uses, among other things, as a brake. When tissue is stressed — when neurons fire too much, inflammation accumulates, sleep is short — extracellular adenosine rises. Caffeine works by blocking that brake.

There are four adenosine receptor subtypes with meaningfully different jobs in pain:

• A1 — broadly inhibitory; spinal activation produces analgesia.
• A2A — context-dependent. Peripherally, can be pro-inflammatory. Spinally and centrally, A2A activation is increasingly recognized as anti-nociceptive, particularly in chronic and neuropathic pain.
• A2B — minor role in pain, larger role in inflammation and asthma.
• A3 — anti-inflammatory and analgesic in chronic neuropathic states.

A2A is the same receptor caffeine antagonizes in your brain to keep you alert, and the target Parkinson’s drugs are built around (istradefylline — the antagonist the Streicher lab uses experimentally — is FDA-approved as Nourianz). What no one had cleanly demonstrated until recently was that several common cannabis terpenes are A2A agonists, and that the agonism is meaningful enough at the spinal cord to produce robust analgesia in living animals.

The 2024 Pain Paper — Mechanism Locked Down

The foundational paper is LaVigne et al., published in Pain in 2024 (PMID 38709489; DOI 10.1097/j.pain.0000000000003265). The authors tested five terpenes — geraniol, linalool, β-pinene, α-humulene, and β-caryophyllene — in a chemotherapy-induced peripheral neuropathy (CIPN) mouse model, the gold-standard rodent model for hard-to-treat neuropathic pain.

Each terpene was dosed at 200 mg/kg intraperitoneal. Active comparators were morphine at 10 mg/kg and WIN55,212-2 at 3.2 mg/kg (a synthetic full-agonist cannabinoid). All five terpenes produced antinociception comparable to those reference drugs in the CIPN model.

Then the authors ran the work that makes this paper matter. To establish which receptor the terpenes were acting through, they used four orthogonal approaches:

1. Pharmacological antagonism. Pre-treatment with istradefylline, a selective A2A antagonist, blocked terpene analgesia. CB1 and CB2 antagonists did not.
2. Genetic knockdown. CRISPR knockdown of A2A in the spinal cord eliminated terpene analgesia.
3. In vitro binding. Terpenes acted as partial agonists at A2A in cell-based functional assays.
4. Molecular modeling. Docking placed the terpenes in plausible A2A binding pockets.

Antagonism plus knockdown plus binding plus structure is about as comprehensive a mechanistic case as a single paper makes. These terpenes relieve neuropathic pain by activating spinal-cord A2A receptors, not CB1 or CB2.

One more finding consumers should know: the terpenes produced no conditioned place preference — the standard rodent assay for reward and abuse liability. Morphine robustly produced reward in the same setup. Whatever else the terpenes are doing, they are not lighting up the dopaminergic circuits opioids do.

How Big Was the Effect, Really?

“Comparable to morphine” deserves precision. Terpenes at 200 mg/kg IP elevated mechanical pain thresholds about as much as morphine at 10 mg/kg IP — a 20:1 dose ratio in favor of morphine, meaning per-milligram morphine is far more potent. But the maximum analgesic effect terpenes reach is on the same order of magnitude as the morphine peak, which is what “comparable efficacy” means in pharmacology.

The other relevant number: low-dose terpene (100 mg/kg) plus low-dose morphine (3.2 mg/kg) produced synergistic pain relief — more than the sum of the parts. The opioid-sparing implications, if they translate to humans, are not small.

The Follow-Up Papers — More Pain Models, Same Mechanism

Mechanism papers often look great in one model and disappear in another. The Streicher group ran two follow-ups in different pain models with the same A2A-blocking design.

Seekins et al., Pharmacology Reports, 2025 (PMID 39663308). Geraniol, linalool, β-caryophyllene, and α-humulene at 200 mg/kg IP produced antinociception in post-operative incisional pain (surgical paw-incision) and fibromyalgia-like pain (reserpine-induced). Istradefylline blocked the effect in both models. Geraniol was the most potent, followed by linalool and α-humulene. Same receptor, different pain syndromes.

Schwarz et al., Neuroscience Letters, 2025 (PMID 40122228). The most translationally important of the three. Instead of single isolated terpenes, the authors tested whole terpene blends extracted from three actual cannabis chemovars. Mixed extracts produced cannabimimetic behaviors and CIPN analgesia at 200 mg/kg. β-Myrcene-dominant blends carried the analgesia; a D-limonene-dominant blend did not. Istradefylline blocked it. The pathway from “purified terpenes in a vial” to “what comes out of a flower” survived — the closest thing yet to evidence the A2A mechanism is engaged when consumers inhale dispensary product, not only when isolated terpenes are injected at supra-physiological doses.

Which Terpenes Did What

Pulling the four papers together:

• β-Myrcene. Strongest evidence in whole-blend work; A2A-dependent in the 2025 Neuroscience Letters paper. The terpene consumers already associate with “couch-lock” indica varieties — see our myrcene primer.
• Geraniol. Among the most potent across post-op and fibromyalgia models. Background: the geraniol piece.
• Linalool. Potent across CIPN, post-op, and fibromyalgia, with separate sedative and anxiolytic activity. See the lavender terpene for calm and sleep.
• β-Caryophyllene. Active in all three pain models — and uniquely complicated because it also binds CB2 directly. More below.
• α-Humulene. Active in CIPN, post-op, and fibromyalgia.
• β-Pinene. Active in CIPN. See our pinene coverage for high-pinene cultivars.
• D-Limonene. Did not produce analgesia in the whole-blend study. A useful negative: not every terpene is an A2A agonist, and analgesic activity tracks specific molecular structures, not “terpenes” as a category. Limonene’s activity sits elsewhere — see our limonene explainer.

The Caryophyllene Wrinkle

β-Caryophyllene has been famous in cannabinoid pharmacology for years because it is a selective CB2 agonist, and CB2 activation is itself analgesic in inflammatory and neuropathic pain — covered in our deep-dive on the terpene that acts like a cannabinoid.

What the new A2A literature adds: caryophyllene is plausibly working through two analgesic pathways at once — CB2 in immune cells and on neurons, plus A2A in the spinal cord. That dual mechanism is unusual, and it is a candidate explanation for why caryophyllene keeps showing up in pain studies as one of the more reliably useful terpenes for inflammatory pain. Drug developers usually have to engineer multi-target activity deliberately. β-Caryophyllene appears to do it natively.

Why This Reframes the Entourage Effect

The original entourage-effect framework, articulated most influentially by Ethan Russo’s 2011 British Journal of Pharmacology review, proposed that terpenes modulate THC and CBD activity — softening intoxication, shifting subjective effects, adjusting therapeutic outcomes. The mechanisms gestured at were mostly indirect: blood-brain-barrier effects, GABAergic and serotonergic signaling, allosteric modulation of cannabinoid receptors.

The A2A finding upgrades that picture meaningfully. Terpenes are not only modulating cannabinoid signaling. They are independent pharmacological agents acting on entirely different receptor systems. When you consume a high-myrcene flower, you are not just getting THC plus flavoring — you are getting THC working at CB1, myrcene working at A2A, caryophyllene at CB2, plus minor cannabinoids touching their own targets.

The “entourage” is not metaphorical. It is multi-pathway polypharmacology — the kind of profile rational drug design rarely produces because regulators prefer single-target compounds. The cannabis plant doesn’t care about regulatory tidiness. It produces dozens of bioactive molecules that hit a half-dozen receptor systems simultaneously, and the net clinical effect emerges from the whole. This is also why isolate products underperform whole-flower in pain trials: a pure THC distillate omits the A2A pathway entirely.

What This Means for Strain Selection

The reframe is real. A high-myrcene strain is not just “sedating.” It is a vehicle for delivering a documented A2A agonist to your spinal cord at a meaningful dose. A high-caryophyllene strain is a dual CB2/A2A actor. A pinene-forward strain brings a third A2A-active compound into the mix.

The Relief family on TIWIH is curated around exactly this polypharmacology — myrcene, caryophyllene, linalool, and pinene appearing together at meaningful percentages. The Balance family sits adjacent for milder profiles. Cultivars worth examining for myrcene-plus-caryophyllene loads include Granddaddy Purple, Grape Ape, and Northern Lights.

Bench-to-Bedside Reality Check

It would be bad pharmacology not to name the limits of mouse-IP-200-mg/kg work:

Dose translation is non-trivial. 200 mg/kg in a mouse, scaled by body surface area, lands around 16 mg/kg in a 70-kg human — roughly 1.1 grams of pure isolated terpene. A typical flower is 1–3% terpene by dry weight, so a gram of high-quality flower contains 10–30 mg total terpenes. Inhalation delivers a fraction of that to circulation. Rodent analgesic doses are not the doses a single joint produces in a person.

Inhaled vs injected pharmacokinetics differ. IP injection delivers high systemic concentrations rapidly; inhaled terpenes reach the lungs first, then redistribute, with substantial first-pass losses.

Animal pain models are imperfect. CIPN, post-op, and fibromyalgia models capture useful aspects of human pain but miss the central-sensitization and affective components that often dominate chronic suffering.

The honest read: the mechanism is established — terpenes are A2A agonists in living tissue, and the pathway produces analgesia. The clinical relevance at consumer doses is plausible and observationally supported, but not yet confirmed in randomized human trials. We are roughly where cannabis-and-migraine sat before the Schuster RCT — promising, mechanistically coherent, awaiting causal confirmation in people.

Practical Implications for Pain Consumers

Read terpene panels. State-mandated COAs increasingly publish terpene percentages. Look for measurable β-myrcene, β-caryophyllene, linalool, and pinene — not just total cannabinoid numbers.

Don’t dismiss “less potent” flower. A flower at 18% THC with 2% total terpenes may outperform 28% THC at 0.4% terpenes for pain because the polypharmacology is richer.

Whole flower and full-spectrum extracts beat distillates for the A2A pathway. Distillates strip volatile terpenes by design.

Combination matters. The mechanism favors broad terpene profiles over single-terpene dominance.

Track what works. Pain is heterogeneous and A2A responsiveness likely is too. The only data that matters for your pain is your logged outcomes against the terpene profiles you actually consumed. Background reading: our pain management guide and cannabis vs. opioids deep-dive.

What Comes Next

Human PK/PD studies on inhaled terpenes are needed to bridge rodent and consumer doses. Combination trials of terpene-rich flower versus distillate would isolate the terpene contribution. The most pressing translational question is opioid-sparing — if a low-dose terpene blend reliably allows half-dose morphine in humans, that is a public-health-scale finding. For now, the molecular biology has caught up to what attentive consumers have been reporting for years: the terpene profile is not an aesthetic detail. It is part of the medicine.

Sources

Primary papers (Streicher lab, University of Arizona):

• LaVigne JE, Hecksel R, Keresztes A, Streicher JM. Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity. Sci Rep. 2021;11(1):8232. doi: 10.1038/s41598-021-87740-8. PMID: 33859287. PubMed
• LaVigne JE, et al. Terpenes from Cannabis sativa induce antinociception in a mouse model of chronic neuropathic pain via activation of adenosine A2A receptors. Pain. 2024;165(7):1573-1585. doi: 10.1097/j.pain.0000000000003265. PMID: 38709489. PubMed
• Seekins CA, Welborn AM, Schwarz AM, Streicher JM. Select terpenes from Cannabis sativa are antinociceptive in mouse models of post-operative pain and fibromyalgia via adenosine A2a receptors. Pharmacol Rep. 2025;77(1):172-181. doi: 10.1007/s43440-024-00687-1. PMID: 39663308. PubMed
• Schwarz AM, Seekins CA, El-Sissi O, Streicher JM. Terpene blends from Cannabis sativa are cannabimimetic and antinociceptive in a mouse chronic neuropathic pain model via activation of adenosine A2a receptors. Neurosci Lett. 2025;854:138205. doi: 10.1016/j.neulet.2025.138205. PMID: 40122228. PubMed

Background and context:

• Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-64. doi: 10.1111/j.1476-5381.2011.01238.x. PMID: 21749363. PubMed
• Sawynok J. Adenosine receptor targets for pain. Neuroscience. 2016;338:1-18. doi: 10.1016/j.neuroscience.2015.10.031. PMID: 26500181. PubMed
• Alfieri A, et al. Phytochemical Modulators of Nociception: A Review of Cannabis Terpenes in Chronic Pain Syndromes. Pharmaceuticals (Basel). 2025. PMID: 40872493. PubMed

A Word From Professor High

The pharmacology nerds have been waiting a long time for someone to take terpene biology seriously enough to run the antagonism-plus-knockdown studies that pin down a mechanism. The Streicher lab did the work. The result is a rare science moment where consumer intuition (“the terps matter for pain”) and rigorous mechanistic data (“here is the receptor”) line up.

The personalization payoff changes how you should shop. THC percentage tells you about intensity. Terpene profile increasingly tells you about therapeutic activity. A pain consumer who learns to read terpene panels is doing something closer to evidence-based medicine than one who only chases potency.

Track which terpene profiles correlate with your relief. Twenty logged sessions — cultivar, terpene panel, dose, route, timing, outcome — start telling a real story about which A2A-active patterns work for your particular pain. Open your TIWIH log here and start building that data.

---

Medical Disclaimer

This article is educational and is not medical advice. The mechanistic studies discussed here are preclinical; rodent analgesia at injected doses is not the same as human analgesia at inhaled doses, and clinical translation is incomplete. Cannabis can interact with prescription medications, may not be appropriate during pregnancy or with certain medical or psychiatric conditions, and carries risks including impairment and dependence. If you are considering cannabis as part of a pain-management plan, discuss it with your physician first.